These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 3930442)

  • 1. Increased radiosensitivity of tumors by perfluorochemicals and carbogen.
    Song CW; Zhang WL; Pence DM; Lee I; Levitt SH
    Int J Radiat Oncol Biol Phys; 1985 Oct; 11(10):1833-6. PubMed ID: 3930442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increase in pO2 and radiosensitivity of tumors by Fluosol-DA (20%) and carbogen.
    Song CW; Lee I; Hasegawa T; Rhee JG; Levitt SH
    Cancer Res; 1987 Jan; 47(2):442-6. PubMed ID: 3098409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increase in tumor pO2 by perfluorochemicals and carbogen.
    Hasegawa T; Rhee JG; Levitt SH; Song CW
    Int J Radiat Oncol Biol Phys; 1987 Apr; 13(4):569-74. PubMed ID: 3104250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variation in tumor response to fluosol-DA (20%).
    Sasai K; Ono K; Nishidai T; Tsutsui K; Shibamoto Y; Takahashi M; Abe M
    Int J Radiat Oncol Biol Phys; 1989 May; 16(5):1149-52. PubMed ID: 2497093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Fluosol DA 20% and carbogen on the radioresponse of SCK tumors and skin of A/J mice.
    Lee I; Levitt SH; Song CW
    Radiat Res; 1987 Oct; 112(1):173-82. PubMed ID: 3116597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic effect of infused Fluosol-DA/carbogen with ephedrine, flunarizine, or nitroprusside.
    Teicher BA; Holden SA; Northey D; Dewhirst MW; Herman TS
    Int J Radiat Oncol Biol Phys; 1993 Apr; 26(1):103-9. PubMed ID: 8482616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of Fluosol-DA and carbogen breathing on the antitumor effects of cyclophosphamide in vivo.
    Kim GE; Song CW
    Cancer Chemother Pharmacol; 1989; 25(2):99-102. PubMed ID: 2513138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reactions of tumors and normal tissues in mice to irradiation in the presence and absence of a perfluorochemical emulsion.
    Rockwell S; Mate TP; Irvin CG; Nierenburg M
    Int J Radiat Oncol Biol Phys; 1986 Aug; 12(8):1315-8. PubMed ID: 3093416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiosensitization of murine tumors by Fluosol-DA 20%.
    Lee I; Levitt SH; Song CW
    Radiat Res; 1990 Jun; 122(3):275-9. PubMed ID: 2113298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence for macrophage involvement in the enhancement of tumor growth delay with X-ray/Fluosol-DAR/O2 combination therapy.
    Holden SA; Teicher BA; McIntosh NL; Rose CM
    Anticancer Res; 1987; 7(3 Pt B):385-90. PubMed ID: 3115174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Addition of misonidazole, etanidazole, or hyperthermia to treatment with fluosol-DA/carbogen/radiation.
    Teicher BA; Herman TS; Holden SA; Jones SM
    J Natl Cancer Inst; 1989 Jun; 81(12):929-34. PubMed ID: 2525198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addition of a hypoxic cell selective cytotoxic agent (mitomycin C or porfiromycin) to Fluosol-DA/carbogen/radiation.
    Holden SA; Herman TS; Teicher BA
    Radiother Oncol; 1990 May; 18(1):59-70. PubMed ID: 2113698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nicotinamide, Fluosol DA and Carbogen: a strategy to reoxygenate acutely and chronically hypoxic cells in vivo.
    Chaplin DJ; Horsman MR; Aoki DS
    Br J Cancer; 1991 Jan; 63(1):109-13. PubMed ID: 1846549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modification of photodynamic therapy-induced hypoxia by fluosol-DA (20%) and carbogen breathing in mice.
    Fingar VH; Mang TS; Henderson BW
    Cancer Res; 1988 Jun; 48(12):3350-4. PubMed ID: 3130983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of fluosol-DA and oxygenation status on the activity of cyclophosphamide in vivo.
    Teicher BA; Herman TS; Holden SA; Cathcart KN
    Cancer Chemother Pharmacol; 1988; 21(4):286-91. PubMed ID: 3131033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Approaches to defining the mechanism of enhancement by Fluosol-DA 20% with carbogen of melphalan antitumor activity.
    Teicher BA; Holden SA; Jacobs JL
    Cancer Res; 1987 Jan; 47(2):513-8. PubMed ID: 3098413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxygenation effect of fluosol-DA on hypoxic tumor tissue and retention of PFCs in the tumor-bearing rats.
    Watanabe M; Okamoto H; Ohyanaqi H; Saitoh Y; Yano K; Tsuda Y; Ueda Y; Yokoyama K
    Biomater Artif Cells Artif Organs; 1988; 16(1-3):547-56. PubMed ID: 3140922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical studies of a perfluorochemical emulsion as an adjunct to radiotherapy.
    Rockwell S; Irvin CG; Kelley M
    Int J Radiat Oncol Biol Phys; 1988 Oct; 15(4):913-20. PubMed ID: 3141320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of fluosol-DA/carbogen on etoposide/alkylating agent antitumor activity.
    Teicher BA; Bernal SD; Holden SA; Cathcart KN
    Cancer Chemother Pharmacol; 1988; 21(4):281-5. PubMed ID: 3131032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Fluosol-DA and oxygen breathing on adriamycin antitumor activity and cardiac toxicity in mice.
    Teicher BA; Holden SA; Crawford JM
    Cancer; 1988 Jun; 61(11):2196-201. PubMed ID: 3365649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.